#BEGIN_DRUGCARD DB00423

# AHFS_Codes:
12:20.00

# ATC_Codes:
M03BA03

# Absorption:
Rapid. Onset of action is about 30 minutes after oral administration.

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Extra Strength Muscle & Back Pain ASA (Acetylsalicylic acid + Methocarbamol)
Methoxacet Extra Strength (Acetaminophen + Methocarbamol)
Muscle & Back Pain ASA (Acetylsalicylic acid + Methocarbamol)
Muscle & Back Pain Relief Caplets (Acetaminophen + Methocarbamol)
Muscle & Back Pain Relief Extra Strength (Acetylsalicylic acid + Methocarbamol)
Muscle Relaxant and Analgesic (Acetylsalicylic acid + Methocarbamol)
Muscle and Back Pain Relief with Asa (Acetylsalicylic acid + Methocarbamol)
Muscle and Back Pain Relief-8 (Acetaminophen + Codeine Phosphate + Methocarbamol)
Robaxacet (Methocarbamol + Acetaminophen)

# Brand_Names:
AHR 85
Avetil
Delaxin
Etroflex
Forbaxin
Glycerylguaiacolate carbamate
Glycerylguajacol-Carbamat
Guaiacol glyceryl ether carbamate
Guaiphenesin carbamate
Guaiphenesine carbamate
Lumirelax
Methocal
Metocarbamol
Metocarbamolo
Metofenia
Metofenina
Miolaxene
Miorilas
Miowas
Myolaxene
Neuraxin
Parabaxin
Perilax
Reflexyn
Relestrid
Robamol
Robaxan
Robaxin
Robaxine
Robaxon
Robinax
Romethocarb
Surquetil
Traumacut
Tresortil

# CAS_Registry_Number:
532-03-6

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H15NO5

# Chemical_IUPAC_Name:
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
731110

# Description:
A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)

# Dosage_Forms:
Liquid	Intramuscular
Liquid	Intravenous
Tablet	Oral

# Drug_Category:
Muscle Relaxants, Central

# Drug_Interactions:
Triprolidine	The CNS depressants, Triprolidine and Methocarbamol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.

# Drug_Reference:
2253675	Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G: Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.61

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
7200 mg/L (at 25 °C)

# Food_Interactions:
Avoid alcohol.
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Methocarbamol

# HET_ID:
Not Available

# Half_Life:
1.14-1.24 hours

# InChI_Identifier:
InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)

# InChI_Key:
InChIKey=GNXFOGHNGIVQEH-UHFFFAOYSA-N

# Indication:
For use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00402

# LIMS_Drug_ID:
423

# Mechanism_Of_Action:
The mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

# Melting_Point:
93 °C

# Molecular_Weight_Avg:
241.2405

# Molecular_Weight_Mono:
241.095022595

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/rob1384.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164749506

# Pharmacology:
Methocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.

# Predicted_LogP_Hydrophobicity:
0.63

# Predicted_LogS:
-1.8

# Predicted_Water_Solubility:
4.21e+00 g/l

# Primary_Accession_No:
DB00423

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4107

# PubChem_Substance_ID:
46507761

# RxList_Link:
http://www.rxlist.com/cgi/generic/methocar.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01102

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
COC1=CC=CC=C1OCC(O)COC(N)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include blurred vision, coma, drowsiness, low blood pressure, nausea, and seizures.

# Update_Date:
2013-02-08 16:19:20 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Methocarbamol

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
1460006	Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CA1

# Drug_Target_1_GenBank_ID_Gene:
X05014

# Drug_Target_1_GenBank_ID_Protein:
29600

# Drug_Target_1_GeneCard_ID:
CA1

# Drug_Target_1_Gene_Name:
CA1

# Drug_Target_1_Gene_Sequence:
>786 bp
ATGGCAAGTCCAGACTGGGGATATGATGACAAAAATGGTCCTGAACAATGGAGCAAGCTG
TATCCCATTGCCAATGGAAATAACCAATCCCCTGTTGATATTAAAACCAGTGAAACCAAA
CATGACACCTCTCTGAAACCTATTAGTGTCTCCTACAACCCAGCCACAGCCAAAGAAATT
ATCAATGTGGGGCATTCTTTCCATGTAAATTTTGAGGACAACGATAACCGATCAGTGCTG
AAAGGTGGTCCTTTCTCTGACAGCTACAGGCTCTTTCAGTTTCATTTTCACTGGGGCAGT
ACAAATGAGCATGGTTCAGAACATACAGTGGATGGAGTCAAATATTCTGCCGAGCTTCAC
GTAGCTCACTGGAATTCTGCAAAGTACTCCAGCCTTGCTGAAGCTGCCTCAAAGGCTGAT
GGTTTGGCAGTTATTGGTGTTTTGATGAAGGTTGGTGAGGCCAACCCAAAGCTGCAGAAA
GTACTTGATGCCCTCCAAGCAATTAAAACCAAGGGCAAACGAGCCCCATTCACAAATTTT
GACCCCTCTACTCTCCTTCCTTCATCCCTGGATTTCTGGACCTACCCTGGCTCTCTGACT
CATCCTCCTCTTTATGAGAGTGTAACTTGGATCATCTGTAAGGAGAGCATCAGTGTCAGC
TCAGAGCAGCTGGCACAATTCCGCAGCCTTCTATCAAATGTTGAAGGTGATAACGCTGTC
CCCATGCAGCACAACAACCGCCCAACCCAACCTCTGAAGGGCAGAACAGTGAGAGCTTCA
TTTTGA

# Drug_Target_1_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_1_General_References:
2121614	Lowe N, Brady HJ, Barlow JH, Sowden JC, Edwards M, Butterworth PH: Structure and methylation patterns of the gene encoding human carbonic anhydrase I. Gene. 1990 Sep 14;93(2):277-83.
3104879	Barlow JH, Lowe N, Edwards YH, Butterworth PH: Human carbonic anhydrase I cDNA. Nucleic Acids Res. 1987 Mar 11;15(5):2386.
4207120	Lin KT, Deutsch HF: Human carbonic anhydrases. XII. The complete primary structure of the C isozyme. J Biol Chem. 1974 Apr 25;249(8):2329-37.
4217196	Giraud N, Marriq C, Laurent-Tabusse G: [Primary structure of human B erythrocyte carbonic anhydrase. 3. Sequence of CNBr fragment I and III (residues 149-260)] Biochimie. 1974;56(8):1031-43.
4625868	Andersson B, Nyman PO, Strid L: Amino acid sequence of human erythrocyte carbonic anhydrase B. Biochem Biophys Res Commun. 1972 Aug 7;48(3):670-7.
4632246	Lin KT, Deutsch HF: Human carbonic anhydrases. XI. The complete primary structure of carbonic anhydrase B. J Biol Chem. 1973 Mar 25;248(6):1885-93.
6781336	Omoto K, Ueda S, Goriki K, Takahashi N, Misawa S, Pagaran IG: Population genetic studies of the Philippine Negritos. III. Identification of the carbonic anhydrase-1 variant with CA1 Guam. Am J Hum Genet. 1981 Jan;33(1):105-11.
7866410	Chegwidden WR, Wagner LE, Venta PJ, Bergenhem NC, Yu YS, Tashian RE: Marked zinc activation of ester hydrolysis by a mutation, 67-His (CAT) to Arg (CGT), in the active site of human carbonic anhydrase I. Hum Mutat. 1994;4(4):294-6.
804171	Kannan KK, Notstrand B, Fridborg K, Lovgren S, Ohlsson A, Petef M: Crystal structure of human erythrocyte carbonic anhydrase B. Three-dimensional structure at a nominal 2.2-A resolution. Proc Natl Acad Sci U S A. 1975 Jan;72(1):51-5.

# Drug_Target_1_HGNC_ID:
HGNC:1368

# Drug_Target_1_HPRD_ID:
00265

# Drug_Target_1_ID:
295

# Drug_Target_1_Locus:
8q13-q22.1

# Drug_Target_1_Molecular_Weight:
28739

# Drug_Target_1_Name:
Carbonic anhydrase 1

# Drug_Target_1_Number_of_Residues:
260

# Drug_Target_1_PDB_ID:
1CZM

# Drug_Target_1_Pathway:
Cimetidine Pathway	SMP00232
Esomeprazole Pathway	SMP00225
Famotidine Pathway	SMP00231
Lansoprazole Pathway	SMP00227
Nizatidine Pathway	SMP00233
Omeprazole Pathway	SMP00226
Pantoprazole Pathway	SMP00228
Pirenzepine Pathway	SMP00246
Rabeprazole Pathway	SMP00229
Ranitidine Pathway	SMP00230

# Drug_Target_1_Pfam_Domain_Function:
PF00194	Carb_anhydrase

# Drug_Target_1_Protein_Sequence:
>Carbonic anhydrase 1
ASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEII
NVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHV
AHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFD
PSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVP
MQHNNRPTQPLKGRTVRASF

# Drug_Target_1_Reaction:
H2CO3 = CO2 + H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Reversible hydration of carbon dioxide

# Drug_Target_1_SwissProt_ID:
P00915

# Drug_Target_1_SwissProt_Name:
CAH1_HUMAN

# Drug_Target_1_Synonyms:
CA-I
Carbonate dehydratase I
Carbonic anhydrase I
EC 4.2.1.1

# Drug_Target_1_Theoretical_pI:
7.14

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00423
